全文获取类型
收费全文 | 7708篇 |
免费 | 535篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 41篇 |
儿科学 | 183篇 |
妇产科学 | 179篇 |
基础医学 | 799篇 |
口腔科学 | 132篇 |
临床医学 | 972篇 |
内科学 | 1385篇 |
皮肤病学 | 62篇 |
神经病学 | 786篇 |
特种医学 | 264篇 |
外科学 | 797篇 |
综合类 | 169篇 |
一般理论 | 11篇 |
预防医学 | 1018篇 |
眼科学 | 138篇 |
药学 | 802篇 |
中国医学 | 9篇 |
肿瘤学 | 555篇 |
出版年
2024年 | 3篇 |
2023年 | 34篇 |
2022年 | 27篇 |
2021年 | 156篇 |
2020年 | 106篇 |
2019年 | 177篇 |
2018年 | 182篇 |
2017年 | 158篇 |
2016年 | 190篇 |
2015年 | 198篇 |
2014年 | 262篇 |
2013年 | 380篇 |
2012年 | 572篇 |
2011年 | 583篇 |
2010年 | 308篇 |
2009年 | 285篇 |
2008年 | 500篇 |
2007年 | 577篇 |
2006年 | 568篇 |
2005年 | 606篇 |
2004年 | 553篇 |
2003年 | 482篇 |
2002年 | 452篇 |
2001年 | 98篇 |
2000年 | 73篇 |
1999年 | 103篇 |
1998年 | 90篇 |
1997年 | 76篇 |
1996年 | 71篇 |
1995年 | 53篇 |
1994年 | 41篇 |
1993年 | 50篇 |
1992年 | 38篇 |
1991年 | 17篇 |
1990年 | 23篇 |
1989年 | 12篇 |
1988年 | 15篇 |
1987年 | 18篇 |
1986年 | 23篇 |
1985年 | 21篇 |
1984年 | 18篇 |
1983年 | 18篇 |
1982年 | 18篇 |
1981年 | 17篇 |
1980年 | 11篇 |
1979年 | 9篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 8篇 |
排序方式: 共有8302条查询结果,搜索用时 15 毫秒
1.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
2.
3.
4.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献5.
6.
7.
8.
Lin Alexander J. Kane Liam T. Molitoris Jason K. Smith Deborah R. Dahiya Sonika Badiyan Shahed N. Wang Tony J. C. Kruser Tim J. Huang Jiayi 《Journal of neuro-oncology》2020,146(1):121-130
Journal of Neuro-Oncology - Practice patterns vary for adjuvant treatment of 1p/19q-codeleted oligodendroglioma patients. This study evaluates the outcomes of adjuvant (aRT) versus salvage... 相似文献
9.
10.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献